Gelecekte Nonavalent 9-valent HPV Aşısının Türkiye İçin Kullanılabilirliği

İlker Selçuk; Yaprak Engin Üstün

Future Feasibility Of Nonavalent 9-valent HPV Vaccine in Turkey

Year 2019, Volume: 16 Issue: 1, 41 - 44, 01.01.2019

Abstract

HPV infection is the most important reason for the development of cervical cancer and HPV type 16 and 18 are responsible for 70% of cervical cancer cases. Bivalent and quadrivalent HPV vaccines are effective against HPV type 16 and 18 among the high risk HPV group, however Nonavalent HPV vaccine provides additional effectiveness against HPV type 31, 33, 45, 52 and 58 among the high risk HPV group. Endemic HPV types detected in Turkey; 16, 51, 31, 52, 56, 39, 58 45, 33 and 18, clearly indicate the need for Nonavalent HPV vaccine for Turkey.

Keywords

HPV, vaccine, cervical cancer, wart, CIN

References

Doorbar J. Molecular biology of human papillomavirus infection and cer- vical cancer. Clin Sci (Lond). 2006;110(5):525-41.
Schiffman M, Wentzensen N. Human papillomavirus infection and the multistage carcinogenesis of cervical cancer. Cancer Epidemiol Biomar- kers Prev. 2013;22(4):553-60.
Chan PK, Chang AR, Yu MY, Li WH, Chan MY, Yeung AC, et al. Age distri- bution of human papillomavirus infection and cervical neoplasia reflects caveats of cervical screening policies. Int J Cancer. 2010;126(1):297- 301.
Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associ- ated with cervical cancer. N Engl J Med. 2003;348(6):518-27.
Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev. 2003;16(1):1-17.
Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, et al. Global burden of human papillomavirus and related disea- ses. Vaccine. 2012;30 Suppl 5:F12-23.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86.
Gultekin M, Kucukyildiz I, Karaca MZ, Dundar S, Boztas G, Turan SH, et al. Trends of Gynecological Cancers in Turkey: Toward Europe or Asia? Int J Gynecol Cancer. 2017;27(8S Suppl 1):S1-S9.
Gultekin M, Dundar S, Kucukyildiz I, Karaca MZ, Boztas G, Turan SH, et al. Survival of gynecological cancers in Turkey: where are we at? J Gynecol Oncol. 2017;28(6):e85.
Beutner KR, Tyring S. Human papillomavirus and human disease. Am J Med. 1997;102(5A):9-15.
McCredie MR, Sharples KJ, Paul C, Baranyai J, Medley G, Jones RW, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol. 2008;9(5):425-34.
Vink MA, Bogaards JA, van Kemenade FJ, de Melker HE, Meijer CJ, Berkhof J. Clinical progression of high-grade cervical intraepithelial ne- oplasia: estimating the time to preclinical cervical cancer from doubly censored national registry data. Am J Epidemiol. 2013;178(7):1161-9.
Safaeian M, Solomon D, Castle PE. Cervical cancer prevention--cer- vical screening: science in evolution. Obstet Gynecol Clin North Am. 2007;34(4):739-60, ix.
Gultekin M, Zayifoglu Karaca M, Kucukyildiz I, Dundar S, Boztas G, Semra Turan H, et al. Initial results of population based cervical cancer screening program using HPV testing in one million Turkish women. Int J Cancer. 2018;142(9):1952-8.
Mayrand MH, Duarte-Franco E, Coutlee F, Rodrigues I, Walter SD, Ratnam S, et al. Randomized controlled trial of human papillomavirus testing ver- sus Pap cytology in the primary screening for cervical cancer precursors: design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST). Int J Cancer. 2006;119(3):615-23.
Ronco G, Dillner J, Elfstrom KM, Tunesi S, Snijders PJ, Arbyn M, et al. Efficacy of HPV-based screening for prevention of invasive cervical can- cer: follow-up of four European randomised controlled trials. Lancet. 2014;383(9916):524-32.
Stanley M. HPV - immune response to infection and vaccination. Infect Agent Cancer. 2010;5:19.
Stanley M. Prophylactic HPV vaccines. J Clin Pathol. 2007;60(9):961-5.
Harper DM, DeMars LR. HPV vaccines - A review of the first decade. Gynecol Oncol. 2017;146(1):196-204.
Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004;364(9447):1757-65.
Villa LL, Ault KA, Giuliano AR, Costa RL, Petta CA, Andrade RP, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine. 2006;24(27- 28):5571-83.
Mariani L, Preti M, Cristoforoni P, Stigliano CM, Perino A. Overview of the benefits and potential issues of the nonavalent HPV vaccine. Int J Gynae- col Obstet. 2017;136(3):258-65.
Palefsky JM, Giuliano AR, Goldstone S, Moreira ED, Jr., Aranda C, Jessen H, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011;365(17):1576-85.
Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Whe- eler CM, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis. 2009;199(7):926-35.
Wheeler CM, Castellsague X, Garland SM, Szarewski A, Paavonen J, Naud P, et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13(1):100-10.
Huh WK, Joura EA, Giuliano AR, Iversen OE, de Andrade RP, Ault KA, et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent hu- man papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial. Lancet. 2017;390(10108):2143-59.
Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711-23.
Olsson SE, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Whe- eler CM, et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evi- dence of prior vaccine type HPV infection. Hum Vaccin. 2009;5(10):696- 704.
Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374(9686):301-14.
World Health Organization. Electronic address swi. Human papillomavirus vaccines: WHO position paper, May 2017-Recommendations. Vaccine. 2017;35(43):5753-5.
Phillips A, Patel C, Pillsbury A, Brotherton J, Macartney K. Safety of Human Papillomavirus Vaccines: An Updated Review. Drug Saf. 2018;41(4):329-46.
Moreira ED, Jr., Block SL, Ferris D, Giuliano AR, Iversen OE, Joura EA, et al. Safety Profile of the 9-Valent HPV Vaccine: A Combined Analysis of 7 Phase III Clinical Trials. Pediatrics. 2016;138(2).
Kosalaraksa P, Mehlsen J, Vesikari T, Forsten A, Helm K, Van Damme P, et al. An open-label, randomized study of a 9-valent human papillomavi- rus vaccine given concomitantly with diphtheria, tetanus, pertussis and poliomyelitis vaccines to healthy adolescents 11-15 years of age. Pediatr Infect Dis J. 2015;34(6):627-34.
Schilling A, Parra MM, Gutierrez M, Restrepo J, Ucros S, Herrera T, et al. Coadministration of a 9-Valent Human Papillomavirus Vaccine With Meningococcal and Tdap Vaccines. Pediatrics. 2015;136(3):e563-72.